Biomarkers for aggressive prostate cancer
US9891224B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 30, 2013 |
| Grant date | Feb 13, 2018 |
| Priority date | — |
| Expiry date | Nov 25, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/56
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing aggressive prostate cancer. In one embodiment, a method for identifying patients as having or likely to have aggressive prostate cancer comprises the steps of (a) obtaining a biological sample from the patient; (b) performing an assay on the biological sample to detect fucosylated fucosylated DPP-4, sTIE-2, sVEGFR-1, and FUT8; and (c) identifying the patient as having or likely to have aggressive prostate cancer if there is a statistically significant difference in the levels of fucosylated TIMP-1, fucosylated DPP-4, sTIE-2, sVEGFR-1 and FUT8.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.